<DOC>
	<DOCNO>NCT01347255</DOCNO>
	<brief_summary>The purpose study evaluate anti-psoriatic effect LEO 90100 cutaneous spray ointment , use psoriasis plaque test modify method develop KJ Dumas JR Scholtz .</brief_summary>
	<brief_title>A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray , Ointment , Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>1 . Subjects sign date informed consent 2 . Age 18 year 3 . Either sex 4 . All skin type 5 . Subjects diagnosis psoriasis vulgaris lesion locate arm , leg and/or trunk . 1 . Females pregnant , childbearing potential wish become pregnant study , breast feeding 2 . Systemic treatment biological therapy ( market market ) possible effect psoriasis vulgaris within 4 week ( etanercept ) , 2 month ( adalimumab , alefacept , infliximab ) , 4 month ( ustekinumab ) 4 weeks/5 halflives ( whichever longer ) experimental biological product prior randomisation study 3 . Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 4 week period prior randomisation study 4 . Use phototherapy within follow time period prior randomisation study : PUVA Grenz ray therapy ( 4 week ) UVB ( 2 week ) 5 . Subjects use one follow topical drug within 4 week prior randomisation study : Potent potent ( WHO group IIIIV ) corticosteroids 6 . Subjects use one follow topical drug treatment psoriasis within 2 week prior randomisation study : WHO group III corticosteroid ( except use treatment scalp and/or facial psoriasis ) Topical retinoids Vitamin D analogues Topical immunomodulators ( e.g . calcineurin inhibitor ) Anthracen derivative Tar Salicylic acid 7 . Subjects use emollient target plaque within one week randomisation study 8 . Initiation , expect change concomitant medication may affect psoriasis vulgaris ( e.g. , beta blocker , antimalaria drug , lithium ACE inhibitor ) within 2 week prior randomisation study 9 . Subjects current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis 10 . Subjects known/suspected disorder calcium metabolism associate hypercalcemia within last 10 year , base medical history 11 . Subjects follow condition present test area : viral ( e.g . herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection atrophic skin 12 . Subjects skin manifestation relation syphilis tuberculosis , rosacea , perioral dermatitis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , acne rosacea , ulcer wound within plaque test area 13 . History severe disease serious current condition ( base subject interview and/or result screen physical examination ) , opinion Investigator , would put subject risk participating study would interfere significantly evaluation study result study course ( e.g . cancer , severe cardiopathy , severe renal insufficiency , severe hepatic insufficiency ) 14 . Subjects receive treatment nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within 4 week period prior randomisation longer , class substance require long washout define ( e.g. , biological treatment ) 15 . Subjects current participation interventional clinical trial , base interview subject 16 . Subjects know suspected hypersensitivity component ( ) investigational product 17 . Subjects concomitant medical dermatological disorder ( ) might preclude accurate evaluation psoriasis 18 . Subjects foresee intensive solar exposure study ( UV radiation , etc . ) expose within two week precede screen visit 19 . Subjects impossible contact case emergency 20 . Subjects know , opinion investigator , unlikely comply Clinical Study Protocol ( e.g . alcoholism , drug dependency psychotic state ) 21 . Subjects exclusion period National Biomedical Research Register French Ministry Health randomisation 22 . Subjects guardianship , hospitalize public private institution , reason research subject deprive freedom 23 . Subjects previously randomise trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>